

Exhibit 18

US Long-Acting Insulin Therapies

AWP Annual Cost of Therapy (\$)

Based upon 50 unit dose

Company/Year Launch	<u>Lantus</u>	<u>Levemir</u>
	Sanofi (2000)	Novo Nordisk (2005)
2003	\$978	-
2004	1,162	-
2005	1,318	-
2006	1,405	\$1,528
2007	1,545	1,582
2008	1,776	1,776
2009	1,883	1,883
2010	2,176	2,206
2011	2,500	2,492
2012	2,886	2,959
2013	4,189	4,189
2014	5,442	5,442
2015	5,442	5,891
2016	5,442	5,891
2017	5,606	5,891
2018	\$5,903	\$6,127

Source: Redbook/Truven.

From the SDNY Whistleblower Complaint filed August 3, 2018